Merck and Bristol-Myers Squibb continue to their race in immuno-oncology, a popular research area. On Monday, Merck announced that it will apply for approval of its melanoma drug, Keytruda, for treatment of lung cancer, in the first half of 2015. The company intends to files its first-in-class cancer immunotherapy specifically …